A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of M701, a Recombinant Epcam and CD3 Bispecific Antibody , in Patients With Malignant Pleural Effusions Caused by NSCLC
Overview
- Phase
- Phase 1
- Intervention
- M701 pleural infusion
- Conditions
- Malignant Pleural Effusions
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Enrollment
- 96
- Locations
- 1
- Primary Endpoint
- Dose Limiting Toxicities (DLTs)
- Status
- Recruiting
- Last Updated
- 9 months ago
Overview
Brief Summary
This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.
Detailed Description
This study is consisted of two phase, Phase Ib and II: Phase 1b includes dose escalation phase and cohort expansion phase. In dose escalation phase, up to 4 dose-escalation cohorts will be sequentially enrolled with regular "3+3" design. DLTs will be evaluated during the first treatment cycle, which is 28 days. In cohort expansion phase, after the RP2D was identified, participants were enrolled in an open-ended manner. Participants were assigned to groups A(3 injections), B (4 injections)and C(6 injections) on a 1:1:1 basis to evaluate the dose frequency. Phase II:The dose and dosing frequency of M701 drug for the Phase II clinical trial were determined based on a combination of the tolerance1 and efficacy of M701 in the Phase Ib trial. Then the participants were randomly divided into two groups: the test group(M701) and the control group(cisplatin or pleural effusions suctions). The pleural effusions response (ORR) and Puncture Free Survival （PuFS）will be evaluated.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males or females, aged \> 18 years.
- •Histologically- or cytologically-confirmed non-small cell lung cancer that has progressed after first line systemic therapy.
- •Malignant pleural effusion diagnosed histologically or cytologically, with moderate or above moderate pleural fluid (sitting pleural fluid depth ≥ 4 cm via ultrasound, expected pleural fluid volume ≥ 500 mL) . Require clinical intervention and not treated yet.
- •Patients who have an washout period of ≥ 4 weeks or 5 half-life of the drug (including radiotherapy, chemotherapy, immunotherapy, biologic, targeted, hormonal therapy, and 14 days for local radiotherapy) between the last systemic therapy and the first dose; however, no washout period is required if the subject has new pleural fluid or poor control of current pleural fluid after at least 2 cycle systemic therapy.
- •Patients who had recovered to grade 0-1 of any toxic reaction to prior antineoplastic therapy as determined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) V5.0, with the exception of alopecia, hyperpigmentation and ≤ grade 2 neuropathy, hormone replacement hypothyroidism or other adverse events confirmed to have turned chronic.
- •Patients with physical status ECOG score (PS) of 0-
- •Patients with life expectancy ≥ 12 weeks.
- •Bone marrow: absolute neutrophil count (ANC) ≥ 1.5 ×10\^9/L, platelet count ≥ 100 ×10\^9/L, hemoglobin ≥ 8.5 g/dL (without blood transfusion within14 days of the first dose of study drug); Liver: bilirubin (TBIL)≤ 1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 3 x ULN ( ≤ 5 x ULN in case of liver metastases); Kidney: serum creatinine ≤1.5 x ULN.
- •Patients must understand and voluntarily sign the written informed consent.
Exclusion Criteria
- •Patients with asymptomatic pleural fluid and not requiring clinical intervention, or bilateral malignant pleural fluid, or proposed perfusion of the chest cavity presenting with pleural fluid separation.
- •Patients with central nervous system (CNS) metastases resulting in clinical symptoms or requiring therapeutic intervention; patients previously treated for brain metastases may be enrolled if they have been asymptomatic for ≥ 4 weeks prior to the first dose and have imaging indicating stable disease and do not require corticosteroid or anticonvulsant therapy.
- •Patients with a known history of severe allergy to M701 drug components or antibody-like macromolecular drugs.
- •Patients with contraindications to thoracentesis.
- •Patients who have undergone major surgical procedures within 4 weeks prior to the first dose.
- •Patients with extensive liver metastases (\>70%).
- •Patients with uncontrollable active infection (NCI-CTCAE V5.0 ≥ grade 2).
- •Patients required long-term hormonal or immunosuppressive therapy, e.g. active autoimmune disease, maintenance therapy after organ transplantation, except that the following are allowed to enter screening: type I diabetes mellitus, hypothyroidism that can be controlled by replacement therapy only, skin diseases that do not require systemic therapy (e.g. vitiligo, psoriasis or alopecia).
- •Patients with severe respiratory disease which, in the judgment of the investigator, makes them unsuitable for entry; or combined interstitial pneumonia.
- •Patients with history of severe cardiovascular disease, including previous coronary artery bypass grafting or coronary stenting, myocardial infarction within 6 months, congestive heart failure (New York Classification of Cardiac Function Class III-IV) or unstable angina, or uncontrolled hypertension.
Arms & Interventions
Experimental group
Pleural drainage and M701 infusion
Intervention: M701 pleural infusion
Experimental group
Pleural drainage and M701 infusion
Intervention: Pleural drainage
Control group
Pleural drainage only or plus chemotherapy as investigator's choice.
Intervention: Pleural drainage
Control group
Pleural drainage only or plus chemotherapy as investigator's choice.
Intervention: Cisplatin pleural infusion
Outcomes
Primary Outcomes
Dose Limiting Toxicities (DLTs)
Time Frame: From the time of the first dose (Day 1) until the forth dosing (Day 28)
Dose limiting toxicities during the first 28 days after the first administrations of study drug in each cohort.
Incidence of AEs
Time Frame: From the start of administration to the end of the study or 28 days after the administration is stopped
Incidence and severity of AEs, including but not limited to vital signs, physical examination, laboratory tests. All AEs will be classified as Grades 1 through 5 as defined by NCI CTCAE v5.0.
Objective Response Rate(4 weeks/8 weeks) of pleural effusion
Time Frame: From the time of first dosing (Day 1) until disease progression(up to 56 days)
the rate of patients with pleural effusion CR and PR at 4 weeks / 8 weeks, based on CT evaluation .
Secondary Outcomes
- Area under the curve (AUC) of M701(From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days))
- Maximum observed concentration (Cmax) of M701(From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days))
- Minimum observed concentration (Cmin) of M701(From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days))
- Half-time (t1/2) of M701(From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days))
- Anti-drug antibodies(ADAs) titer(From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days))
- Neutralizing antibody titer(From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 16 days))
- Concentrations of tumor biomarker in pleural effusions(From the time of first dosing (Day 1) until disease progression or toxicity intolerance(up to 56 days))
- Expression level of EpCAM-positive cells in pleural effusions(From the time of first dosing (Day 1) until disease progression (up to 56 days))
- Ratio of EpCAM-positive tumour cell/leucocyte(From the time of first dosing (Day 1) until disease progression (up to 56 days))
- Rate of with successful pleurodesis (4/8 weeks)(From the time of first dosing (Day 1) until disease progression (up to 56 days))
- Puncture-free survival rate at 4/8 weeks(From the time of first dosing (Day 1) until disease progression (up to 56 days))
- Pleural signs and symptoms(From the time of first dosing (Day 1) until disease progression (up to 56 days))